Fidelity Management & Research Co recently announced the acquisition of new stake in Seres Therapeutics Inc (NASDAQ:MCRB). The institutional investor has increased its shareholding in the Healthcare company by 0.24% to 19.23 million shares with purchase of 45484.0 shares. This fresh investment now brings its stake to 14.88% valued currently at $20.0 million. In addition, SSgA Funds Management, Inc. raised its holdings by 0.97 million to 9.54 million shares. And BlackRock Fund Advisors has lifted its position by 5.31% or 0.36 million shares – to 7.06 million shares.
Currently, there are 125.22M common shares owned by the public and among those 97.45M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 19 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 175,556 shares. Insider sales of the common stock occurred on 9 occasions, with total insider shares sold totaling 41,807 shares.
The top 3 mutual fund holders in Seres Therapeutics Inc are Federated Hermes Kaufmann Fund, SPDR S&P Biotech ETF, and Fidelity Growth Company Fund. Federated Hermes Kaufmann Fund owns 8.76 million shares of the company’s stock, all valued at over $9.11 million. The company sold -2.31 million shares recently to bring their total holdings to about 6.77% of the shares outstanding. SPDR S&P Biotech ETF bought 38355.0 shares to see its total holdings expand to 8.23 million shares valued at over $8.56 million and representing 6.37% of the shares outstanding. Fidelity Growth Company Fund now owns shares totaling to 4.54% of the shares outstanding.
However, the script later moved the day high at 1.2261, up 13.84%. The company’s stock has a 5-day price change of 13.35% and -59.21% over the past three months. MCRB shares are trading -79.82% year to date (YTD), with the 12-month market performance down to -80.65% lower. It has a 12-month low price of $0.91 and touched a high of $6.87 over the same period. MCRB has an average intraday trading volume of 3.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.77%, -10.45%, and -70.50% respectively.
Institutional ownership of Seres Therapeutics Inc (NASDAQ: MCRB) shares accounts for 65.32% of the company’s 125.22M shares outstanding. Mutual fund holders own 27.55%, while other institutional holders and individual stakeholders account for 37.80% and 17.76% respectively.
It has a market capitalization of $146.06M and a beta (3y monthly) value of 2.29. The earnings-per-share (ttm) stands at -$1.13. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.86% over the week and 13.51% over the month.
Earnings per share for the fiscal year are expected to increase by 57.39%, and -33.94% over the next financial year.
Looking at the support for the MCRB, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on June 26, 2023, with the firm’s price target at $12.
